Research programme: anti viral therapeutics - Center for Genetic Engineering and Biotechnology

Drug Profile

Research programme: anti viral therapeutics - Center for Genetic Engineering and Biotechnology

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Peptides
  • Mechanism of Action Adhesion receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dengue

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 31 Dec 2015 Research programme: anti viral therapeutics - Center for Genetic Engineering and Biotechnology is available for licensing as of 31 Dec 2015 http://gndp.cigb.edu.cu/index.php/pipeline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top